Kura Oncology Inc. and Kyowa Kirin Co. Ltd.’s selective oral menin inhibitor, ziftomenib, met the primary endpoints in the ...

In keeping with the trend in med tech to return to basics, Becton, Dickinson and Co. plans to split off its biosciences and diagnostic solutions unit to create two pure-play companies. The ‘New BD’ or ...

Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...

Europe has more oncology startups than the U.S., but many more U.S. companies scale up to the later growth stage. Given the ...

As pulsed field ablation transformed the electrophysiology market over the last year, Boston Scientific Corp. emerged as the ...

Touting its novel approach for treating glaucoma, Qlaris Bio Inc. reported promising top-line data from two phase II studies testing QLS-111 in patients with primary open-angle glaucoma and ocular ...

Researchers from Sun Yat-sen University and affiliated organizations published data from a study that aimed to assess the role of the TNF receptor-associated factor 6 (TRAF6), E3 ubiquitin ligase ...

Cour Pharmaceuticals Development Co. Inc. has obtained IND clearance from the FDA for CNP-103, a nanoparticle in development to address the underlying autoimmunity of type 1 diabetes. A first-in-human ...

Auron Therapeutics Inc. has received FDA clearance of its IND application for its oral KAT2A/B degrader AUTX-703 in hematological malignancies. A phase I proof-of-concept trial in acute myeloid ...

Co. Ltd. has identified proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an androgen receptor targeting moiety through a linker acting as androgen ...

Navega Therapeutics Inc. has received a $4 million Translational Science grant from the California Institute for Regenerative Medicine (CIRM) to support its work addressing neuropathic pain. The grant ...

Researchers from Astrazeneca plc and Karolinska Institutet have described the positron emission tomography (PET) evaluation of [11C]AZD-2423, a chemokine receptor type 2 (CCR2) radioligand in ...